Retatrutide 20 mg

Triple Receptor Agonist — Metabolic Signaling Research

In plain terms: This compound acts on three separate metabolic receptors at once, rather than just one. Research has focused on how that combined activity relates to body weight and metabolic markers in study populations.

Compound classification: Retatrutide is a synthetic peptide studied as a triple agonist, engaging GLP-1, GIP, and glucagon receptors.

Studied mechanism

Research has examined Retatrutide’s combined activity across all three receptor pathways — GLP-1 and GIP receptor engagement relevant to insulin secretion and appetite-related signaling, alongside glucagon receptor activity linked to energy expenditure.

Research findings: Clinical trial data have examined body weight, fat mass, and metabolic marker changes in study populations, with published results describing greater magnitude of change than single- or dual-receptor agonists studied to date.

Effects reported in research literature:

• Gastrointestinal effects (nausea, decreased appetite) in study subjects

• Injection site reactions

• Fatigue

Research status: Retatrutide remains in clinical investigation; long-term safety and efficacy data outside trial settings are not established.

Research Use Only: This compound is intended for laboratory research use only. It is not a drug, dietary supplement, or consumer product, and is not for human or animal consumption. Statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.